Key facts
- PeproMene Bio’s last known valuation is $114.8M (May 2020).
- It has raised $50.2M across 1 recorded rounds; the latest was Early Stage VC ($40.2M) in Jul 2017.
- Notable investors include KB Investment, Binex (Busan), Binex (Pharmaceutical Company), Institute for Follicular Lymphoma Innovation, Seven Tree Equity Partners — 6 tracked in total.
- PeproMene Bio has filed 1 Form D with the SEC, most recently Jun 2018 ($40.2M sold to 17 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for PeproMene Bio
Funding rounds
1 roundsAbout PeproMene Bio
Operator of a biotechnology company intended to develop novel immune-oncology therapies. The company offers services including developing leukemia-specific immune cell therapy based on novel antibodies, enabling medical researchers to develop oncology treatment therapies and drugs.
- Sector
- Healthcare
- HQ
- Irvine, CA, United States
- Founded
- 2016
- Employees
- 7
- Website
- pepromenebio.com/
- Ownership
- Privately Held (backing)
PeproMene Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PeproMene Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PeproMene Bio in its N-PORT filings yet. We sweep new filings monthly.